Teleflex (TFX) Reaches $246.68 Formed H&S; Epizyme (EPZM) Sentiment Is 1.21

Epizyme, Inc. (NASDAQ:EPZM) Logo

Teleflex Incorporated (TFX) formed H&S with $229.41 target or 7.00% below today’s $246.68 share price. Teleflex Incorporated (TFX) has $11.21 billion valuation. The stock decreased 2.13% or $5.38 during the last trading session, reaching $246.68. About 215,139 shares traded. Teleflex Incorporated (NYSE:TFX) has risen 32.04% since April 7, 2017 and is uptrending. It has outperformed by 20.49% the S&P500.

Epizyme Inc (EPZM) investors sentiment decreased to 1.21 in Q4 2017. It’s down -0.25, from 1.46 in 2017Q3. The ratio turned negative, as 47 funds started new or increased holdings, while 39 cut down and sold their stock positions in Epizyme Inc. The funds in our database now hold: 56.93 million shares, down from 58.04 million shares in 2017Q3. Also, the number of funds holding Epizyme Inc in top ten holdings was flat from 3 to 3 for the same number . Sold All: 15 Reduced: 24 Increased: 35 New Position: 12.

The stock decreased 9.17% or $1.5 during the last trading session, reaching $14.85. About 514,308 shares traded or 15.03% up from the average. Epizyme, Inc. (EPZM) has risen 1.14% since April 7, 2017 and is uptrending. It has underperformed by 10.41% the S&P500.

Foresite Capital Management Ii Llc holds 6.83% of its portfolio in Epizyme, Inc. for 1.56 million shares. Palo Alto Investors Llc owns 6.86 million shares or 3.71% of their US portfolio. Moreover, Nea Management Company Llc has 3.36% invested in the company for 6.46 million shares. The California-based Redmile Group Llc has invested 1.05% in the stock. Oracle Investment Management Inc, a Connecticut-based fund reported 362,892 shares.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.03 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $1.45 million activity.

Since January 2, 2018, it had 0 insider buys, and 9 sales for $4.40 million activity. 2,500 shares were sold by BABICH GEORGE JR, worth $707,775. 1,359 shares valued at $347,449 were sold by Deren John on Tuesday, February 27. $49,792 worth of stock was sold by Klasko Stephen K. M.D. on Tuesday, January 2.

Analysts await Teleflex Incorporated (NYSE:TFX) to report earnings on May, 3. They expect $1.94 earnings per share, up 7.78% or $0.14 from last year’s $1.8 per share. TFX’s profit will be $88.14M for 31.79 P/E if the $1.94 EPS becomes a reality. After $2.44 actual earnings per share reported by Teleflex Incorporated for the previous quarter, Wall Street now forecasts -20.49% negative EPS growth.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.03, from 1.1 in 2017Q3. It increased, as 19 investors sold Teleflex Incorporated shares while 132 reduced holdings. 62 funds opened positions while 108 raised stakes. 39.40 million shares or 0.28% more from 39.29 million shares in 2017Q3 were reported. Leavell Investment Mngmt has invested 0.12% in Teleflex Incorporated (NYSE:TFX). Weaver C Barksdale & Assocs, Tennessee-based fund reported 45 shares. Missouri-based Amer Century Cos Inc has invested 0.37% in Teleflex Incorporated (NYSE:TFX). Solaris Asset Management Limited invested 3.7% in Teleflex Incorporated (NYSE:TFX). Verition Fund Mgmt Lc reported 1,243 shares. Capital Fund reported 0.01% stake. State Treasurer State Of Michigan holds 0.03% or 16,230 shares. Keating Investment Counselors holds 2,543 shares. Sheets Smith Wealth Mngmt owns 2,694 shares. Eagle Asset Management holds 0.03% of its portfolio in Teleflex Incorporated (NYSE:TFX) for 19,175 shares. Oppenheimer Asset Management Inc has 2,373 shares. Lpl Financial Ltd Liability has 0% invested in Teleflex Incorporated (NYSE:TFX). Fiduciary reported 1,325 shares. Cubist Systematic Strategies Ltd Liability has invested 0.02% in Teleflex Incorporated (NYSE:TFX). First Republic Mngmt holds 0.01% in Teleflex Incorporated (NYSE:TFX) or 3,633 shares.

Among 11 analysts covering Teleflex (NYSE:TFX), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Teleflex had 34 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Teleflex Incorporated (NYSE:TFX) earned “Hold” rating by Deutsche Bank on Tuesday, November 14. The firm has “Strong Buy” rating by Raymond James given on Wednesday, January 6. The firm has “Buy” rating given on Tuesday, September 5 by Jefferies. Jefferies maintained the stock with “Buy” rating in Tuesday, October 10 report. The stock of Teleflex Incorporated (NYSE:TFX) has “Outperform” rating given on Friday, February 23 by Leerink Swann. Leerink Swann maintained the shares of TFX in report on Tuesday, January 30 with “Buy” rating. Barclays Capital maintained Teleflex Incorporated (NYSE:TFX) on Monday, June 26 with “Buy” rating. Needham initiated Teleflex Incorporated (NYSE:TFX) rating on Tuesday, March 7. Needham has “Buy” rating and $221 target. Brean Capital maintained Teleflex Incorporated (NYSE:TFX) rating on Friday, July 31. Brean Capital has “Buy” rating and $145 target. As per Friday, January 6, the company rating was upgraded by Jefferies.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart